Key Drivers
- High cash runway
- Zero revenue
- Negative FCF
AIAI Summary
With FDA acceptance of the deramiocel BLA and a PDUFA set for 2026-08-22, Capricor is now an approval/timing-driven investment where near-term upside depends on a favorable label, early payer receptivity and NS Pharma milestone execution—monitor cash runway, milestone receipts and PDUFA guidance closely because restrictive labeling, slow reimbursement or missed milestones would likely force dilutive financing.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash runway
- •Zero revenue
- •Negative FCF
CAPR has ample cash and negligible debt but generated no revenue, sustained large operating losses and negative free cash flow, and is materially dependent on external financing to fund R&D and operations.
Price Behavior
Key Price Behavior Insights:
- •Repeated rebounds
- •Failed breakouts
- •Elevated volatility
CAPR has traded choppily over the last month, repeatedly bouncing into mid‑$20s support but failing at low‑$30s resistance amid elevated volatility and weakening momentum.
Sharp rallies into early
Sentiment & News
Key News Insights:
- •BLA review resumed
- •Strong HOPE-3 data
- •Analyst upgrades
Capricor's FDA resumption of Deramiocel BLA review with an Aug 22 PDUFA, positive HOPE-3 Phase 3 results and FDA acceptance of the study report drove analyst upgrades and stock volatility despite a Q4 earnings miss.
The regulatory momentum and compelling Phase 3 data materially improve approval odds and investor sentiment, likely supporting upside in the stock ahead of the Aug PDUFA date
Similar Companies in Healthcare
Other companies in the same sector with AI ratings